Clinical Trial Update: Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 extension study update for ADX-324 in hereditary angioedema; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ADX-324

Snippet

Sponsor: ADARx Pharmaceuticals, Inc. | Conditions: Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | Phase 3 | Status: NOT_YET_RECRUITING